Table 1 Goblet cell carcinoid outcomes by different chemotherapy regimens
Study | Type of study | N | Stage | Histology | Treatment | CR | PFS | Overall survival |
|---|---|---|---|---|---|---|---|---|
Garin et al. [23] 2002 | Case report | 1 | IV | Adenocarcinoid | 5-FU + LV (LV5FU2) × 1 cycle followed by FOLFOX 4 × 9 months | Yes (at 8 months) | 3 years | – |
Pham et al. [11] 2006 | Retrospective review | 57 | I – 8 II – 20 III – 6 IV – 23 | Goblet cell carcinoid | 5-FU + LV-based chemotherapy (N = 27, Stage II–IV) | – | – | Cx versus No Cx Stage II–III Mean (months): 47 versus 32 months (p = 0.383) 5 year (%): 43 versus 56 Stage IV Mean (months): 39 versus 29 (p = 0.281) 5 year (%): 26 versus 0 |
Toumpanakis et al. [24] 2007 | Retrospective review | 15 | I–IV | Goblet cell appendiceal carcinoid | RH in all patients without metastasis. Stage IV (3) 2- VP-16 + cisplatin 1–5-FU + cisplatin +streptozotocin. | – | 11/15 no disease (median follow-up 30 months) | Median 30 months follow up: − 11 alive with no disease – 1 alive with metastatic disease – 3 died of metastatic disease (9–14 months) |
Tang et al. [13] 2008 | Retrospective review | 63 | I – 2 II – 18 III – 3 IV – 40 Tang group A – 30 B – 26 C – 7 | Goblet cell carcinoid | FOLFOX FOLFIRI (33/63) Stage III (2/3) Group B (14/26) | Group A – 86% Group B – 15% Group C – 0% | DSS % (Tang groups) 3 years Group A – 100% Group B – 85% Group C – 17% 5 years Group A – 100% Group B – 36% Group C – 0% | – |
Bilen et al. [25] 2013 | Case series | 1 | Metastatic | Poorly differentiated adenocarcinoma arising from goblet cell carcinoid | FOLFOX followed by CRS and HIPEC (mitomycin-C) | pCR | Disease free at 7 months | – |
Clift et al. [22] 2018 | Retrospective review | 21 | I – 1 II – 10 III – 5 IV – 5 Tang group A – 8 B – 10 C – 3 | Goblet cell carcinoid | Appendectomy: 12 (completion RH: 8) RH: 6 Other resections: 3 6 received adjuvant cx with CAPOX – 5 dead of disease, 1 alive with no disease | – | DFS: 1-year: 94.7% 3-year: 74.2% 5-year: 74.2% | Mean OS (1-, 3-, and 5-year OS) 80.3 months (79.4%, 60%, and 60%) Group A: 73.1 months (85.7%, 85.7%, 51.4%) Group B: 83.7 months (all 66.7%) Group C: 28.5 months (66.7%, 66.7%, not reached) |